Associated Genetic Biomarkers
PIK3CA D549N is present in 0.02% of AACR GENIE cases, with breast invasive ductal carcinoma, endometrial endometrioid adenocarcinoma, bladder urothelial carcinoma, invasive breast carcinoma, and oropharyngeal squamous cell carcinoma having the greatest prevalence .
PIK3CA D549N serves as an inclusion eligibility criterion in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA D549N as an inclusion criterion, 1 is phase 2 (1 open).
Trials with PIK3CA D549N in the inclusion eligibility criteria most commonly target non-small cell lung carcinoma and breast carcinoma .
Afatinib, docetaxel, durvalumab, fulvestrant, and lapatinib are the most frequent therapies in trials with PIK3CA D549N as an inclusion criteria .
Significance of PIK3CA D549N in Diseases
Breast Carcinoma +
PIK3CA is altered in 36.07% of breast carcinoma patients with PIK3CA D549N present in 0.03% of all breast carcinoma patients .
PIK3CA D549N is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA D549N and breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.